Oruka Therapeutics (ORKA) Cash & Equivalents (2010 - 2026)

Oruka Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $45.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 87.69% year-over-year to $45.4 million; the trailing twelve-month figure through Mar 2026 stood at $45.4 million (down 87.69% YoY), and the FY2025 full-year result was $477.4 million, up 675.31% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $45.4 million, down from $477.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $477.4 million in Q4 2025, with the low at $33.3 million in Q2 2024.
• Average Cash & Equivalents over 5 years is $112.9 million, with a median of $45.4 million recorded in 2026.
• Year-over-year, Cash & Equivalents jumped 947.94% in 2024 and slumped 87.69% in 2026.
• Tracing ORKA's Cash & Equivalents over 5 years: stood at $42.4 million in 2022, then declined by 11.81% to $37.4 million in 2023, then soared by 64.5% to $61.6 million in 2024, then soared by 675.31% to $477.4 million in 2025, then slumped by 90.49% to $45.4 million in 2026.
• The last three Cash & Equivalents figures came in at $45.4 million (Q1 2026), $477.4 million (Q4 2025), and $89.0 million (Q3 2025), per Business Quant data.

Peer Comparison